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Background: Sodium oxybate is licensed in Europe for the treatment of narcolepsy with cataplexy in
adults. The aim of this study was to assess the efﬁcacy and safety of sodium oxybate in clinical practice in
patients with narcolepsy and cataplexy refractory to other treatments.
Materials and methods: This was a retrospective single centre study including patients with severe
narcolepsy with cataplexy refractory to other treatments, who were initiated on sodium oxybate be-
tween 2009 and 2015. Patients were allowed to be on other stimulants or/and anti-cataplectic agents.
Epworth sleepiness scale (ESS) and weekly cataplexy events were recorded. Side effects (SEs) were
recorded at every follow-up visit.
Results: 90 patients were prescribed sodium oxybate, with a total of 3116 patient-months of drug
exposure. ESS and weekly cataplexy events were signiﬁcantly reduced by sodium oxybate for all patients
(DESS ¼ 4.3 ± 4.4 and Dcataplexy ¼ 21.8 ± 18.5 events/week; p < 0.0001, respectively). The required
maintenance dose could not be predicted based upon gender, body mass index, or clinical factors. 60% of
patients were able to reduce or come off other medications. Half of the patients experienced at least one
SE, and 26.6% had to stop treatment due to limiting SEs. Nausea, mood swings and enuresis were the
most commonly reported SEs. SEs that led to drug discontinuation, particularly psychosis, were asso-
ciated with increasing age and were observed early after the initiation of the drug.
Conclusions: Sodium oxybate provides a good clinical efﬁcacy and acceptable safety proﬁle in routine
clinical practice for the treatment of patients suffering from narcolepsy with cataplexy. A quarter of
patients experience SEs requiring withdrawal of the drug with older patients being more vulnerable to
the more serious SEs.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Narcolepsy is a chronic neurological disorder causing dysregu-
lation of sleep andwakefulness, with a prevalence of approximately
1 in 3000 [1]. It is characterised by excessive daytime sleepiness
(EDS), cataplexy, hypnagogic/hypnopompic hallucinations, sleep
paralysis and disturbed sleep [2].
There is no cure for narcolepsy at present, and current treatment
focuses on symptom control. A reduction in daytime sleepiness is
achievable with medications that increase wakefulness, including
wake promoters such as modaﬁnil, amphetamines, and methyl-
phenidate, while cataplexy is typically controlled through the use
of antidepressant drugs which suppress Rapid Eye Movement sleep
[3e6].
Sodium oxybate, the sodium salt of gamma-hydroxybutyrate
(GHB), an endogenous metabolite of gamma-aminobutyric acid
(GABA), is a central nervous system depressant. It is indicated for
the treatment of both cataplexy and EDS associatedwith narcolepsy
[7]. Its mode of action is uncertain, but it may involve stimulation of
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GABA-B receptors [8]. Sodium oxybate is rapidly absorbed and
metabolised, having a mean elimination half-life of 90e120 min. It
is currently authorized by the European Medicines Agency to treat
narcolepsy with cataplexy in adults, and by the US Food and Drug
Administration (FDA) to treat cataplexy in patients with narcolepsy,
with an “expanded indication” for the treatment of EDS [3,9].
Existing data regarding the tolerability and efﬁcacy of sodium
oxybate in narcolepsy originate from prospective drug trials
[10e13]. We aimed to analyse the use of sodium oxybate in routine
European clinical practice, where sodium oxybate is reserved for a
sub-group of patients with narcolepsy with cataplexy, patients
more likely to be on multiple other therapies with a more severe
phenotype.
2. Materials and methods
We performed a retrospective study assessing patients
attending a tertiary referral sleep disorders centre. All patients
diagnosed with narcolepsy with cataplexy and initiated on sodium
oxybate between 2009 and 2015 were included. A full medical
history, sleep history, sleep study results and demographics were
recorded for all patients. The reduction of Epworth Sleepiness Scale
(ESS) score (DESS) and of cataplexy events expressed in events/
week (Dcataplexy) were recorded from patients' notes and relevant
diaries, as the differences between ESS and cataplexy events before
sodium oxybate initiation (baseline) and after a dose of sodium
oxybate providing optimal clinical effect was achieved (ﬁnal).
Due to the nature of the study and the limitations that apply in
the UK for sodium oxybate treatment eligibility, patients could
already be on other drugs for narcolepsy (stimulants or/and anti-
cataplectic agents). According to policies in place for prescribing
of sodium oxybate within the UK National Health Service (NHS),
patients were only eligible for this drug if they had tried at least two
stimulants and/or two anti-cataplectic agents, and remained
symptomatic with an ESS 17 or with an average 21 cataplectic
events per week.
All the patients in this study were initially treated with oral
sodium oxybate 4.5 g/night, given as two equally divided doses
2.5e4 h apart and titrated, according to response, up to a maximum
dose of up to 9 g/night in two doses of 4.5 g each, with dose ad-
justments every two weeks, as stipulated in the approved pre-
scribing protocol. Any subsequent reduction or elimination of other
drugs for narcolepsy was recorded. Appropriate approval from the
institutional review board on human research was obtained
(project number 4641).
3. Diagnosis
The diagnosis of narcolepsy with cataplexy was made according
to the International Classiﬁcation of Sleep Disorders-2 (ICSD-2)
criteria of the American Academy of Sleep Medicine (AASM), due to
the retrospective nature of the study [14].
4. Outcomes analysis
Safety and tolerability were evaluated based on reported side
effects (SEs), without a pre-established list of SEs, during every
follow-up visit after initiation of sodium oxybate. SEs were cate-
gorized into groups: namely infections, psychiatric, neurological,
gastrointestinal, general, sleep disorders and cardiological SEs, in
keeping with those listed in the summary of product characteristics
[15]. Reports from patients' notes of mood changes throughout the
day, which could vary from elevated mood to anger to sadness
within a few hours, and changes in mood clearly out of proportion
to circumstances which could also cause impairment in
functioning, were grouped under the term mood swings. Psychotic
symptoms were conﬁrmed by formal psychiatric assessment and
were made according to the Diagnostic and Statistical Manual of
Mental Disorders ﬁfth edition (DSM-V) criteria [16].
5. Statistics
Results are reported as mean ± SD if not otherwise indicated.
Following testing for normality, comparison between groups was
performed using independent-samples ManneWhitney U test.
Spearman product correlation coefﬁcient was used for correlations
between continuous and nominal variables and Chi Square with
Cramer's V product for correlations between nominal variables.
Comparison of baseline and ﬁnal ESS and cataplexy events within
patients was calculated using related-samples Wilcoxon Signed-
Ranks Test. A multiple stepwise linear regression analysis was
performed to identify which variables most satisfactorily explained
DESS and Dcataplexy in our patients. Binary regression analysis
with forward stepwise method was applied in three prediction
models: 1) to predict which patients exhibited a reduction of other
drugs (wake promoters, stimulants or/and anti-cataplectic agents)
due to sodium oxybate initiation, 2) which experienced any SEs
secondary to sodium oxybate, and 3) which patients had to dis-
continue the drug due to SEs. Statistical signiﬁcance was deﬁned as
p < 0.05. IBM SPSS Statistics V24.0 (SPSS, Chicago, IL/USA) was used
for all statistical analysis.
6. Results
6.1. Efﬁcacy
A total of 90 patients with narcolepsy with cataplexy, aged
42.5± 14.9 years, were prescribed sodium oxybate during the study
period, with a total of 3116 patient-months of drug exposure, and a
median 35.5 months (interquartile range 11.0e54.0) of follow up
time (FU) (Table 1).
Sodium oxybate signiﬁcantly reduced the ESS (DESS ¼ 4.3 ± 4.4,
p < 0.0001). The most common optimal dose of sodium oxybate
was 9 g/night (31/90, 33.3%), but many patients were treated with
lower doses (22.2% required 4.5 g/night, 22% 6 g/night, and 18%
7.5 g/night).
The improvement in ESS (DESS) correlated with higher ﬁnal
dose of the drug (r¼ 0.389, p < 0.001), but no correlationwas found
with age and BMI. A stepwise regression analysis was performed
for predictors of DESS in the group of patients that did not dis-
continue sodium oxybate due to side effects or lack of efﬁcacy. Age,
Table 1
Demographics, baseline characteristics and treatment of the studied cohort.
Parameters (n ¼ 90) Mean ± SD
Age (years) 42.5 ± 14.9
Gender (M/F) 38/52
BMI (kg/m2) 30.1 ± 7.8
*ESS baseline 18.9 ± 3.4
*ESS ﬁnal 14.5 ± 5.1
*Cataplexy events/week baseline 26.2 ± 22.7
*Cataplexy events/week ﬁnal 4.4 ± 10.8
Patients on stimulants or wake promoters, n (%) 36 (40)
Patients on anticataplectic agents, n (%) 7 (7.8)
Patients on combination treatment, n (%) 44 (48.9)
Patients on no treatment, n (%) 3 (3.3)
FU time (months) 35.5 (IQR 11.0e54.0)
BMI, Body Mass Index; ESS, Epworth Sleepiness Scale score. *: Baseline and ﬁnal
term uses as reference points the status before sodium oxybate initiation and after
optimum dose of sodium oxybate had been achieved, respectively. FU, follow-up is
reported as median; IQR, interquartile range. The term combination treatment re-
fers to stimulants or wake promoters and anti-cataplectic agents.
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BMI, gender, number of other concomitant drugs, reduction of
other drug dosages, ﬁnal sodium oxybate dose, and baseline ESS
were added as independent variables. Patients who were sleepier
at baseline were more likely to experience the greatest reduction in
ESS (n ¼ 61, F ¼ 4.876, R ¼ 3.23, adjusted R2 ¼ 0.083, p¼ 0.033). No
difference was found between genders with regard to age, BMI,
baseline ESS, sodium oxybate ﬁnal dose and DESS (p > 0.05).
A similar analysis was performed assessing the efﬁcacy of so-
dium oxybate in controlling cataplexy, demonstrating a signiﬁcant
reduction in frequency of cataplectic events (Dcataplexy
21.8 ± 18.5 events/week; p < 0.0001). There was no correlation
between age, BMI, ﬁnal dose of sodium oxybate, and Dcataplexy. A
stepwise regression analysis assessing predictors of Dcataplexy,
using the same variables outlined above, demonstrated that only
the baseline cataplexy frequency predicted reduction in cataplexy
events (n ¼ 61, F ¼ 137.602, R ¼ 0.898, adjusted R2 ¼ 0.801,
p < 0.0001). There was no difference between genders in the
number of baseline cataplexy events or in Dcataplexy (p > 0.05).
Sixty-one patients were successfully treated with sodium oxybate
(61/90, 67.7%) and all patients except for one were on other drugs
for narcolepsy. Twenty of those (32.8%) were on one or more
stimulant medication, 37 (60.7%) on a combination of stimulant
and anti-cataplectic agents, and three (4.9%) on an anti-cataplectic
agent. The administration of sodium oxybate led to a reduction in
dosage of other drugs in 56% (34/60) of patients, of which the
majority remained on combined treatment (70.6%), but in 10% (6/
60) all other drugs were successfully discontinued. No clear pre-
dictors of a reduction of other medications following initiation of
sodium oxybate initiation could be identiﬁed. In ﬁve patients so-
dium oxybate was ineffective and discontinued.
6.2. Safety and tolerability
A total of 34 possible SEs associated with the administration of
sodium oxybate were recorded from patients' medical records
(Table 2). 55.6% (50/90) of our patients experienced a SE and in
almost half of these cases (48%, 24/50) the drug had to be dis-
continued with subsequent resolution of the SE.
The most common SEs observed were nausea (17.7%), mood
swings (15.5%) and enuresis (12.2%). One patient developed hy-
pertension and three patients with known obstructive sleep apnea
(OSA) required re-titration to higher continuous positive airway
(CPAP) pressures despite no change in BMI or other clinical
variables.
The SEs that led to drug discontinuation were viral infection,
psychosis, suicidal ideation, mood swings, anxiety, headaches,
impaired concentration, dizziness, unresponsiveness, nausea,
vomit, diarrhea, faecal and urinary incontinence, gastroesophageal
reﬂex disease, appetite loss, sweating, facial swelling, bad taste,
pain, enuresis, worse cataplexy, hypertension and palpitations (11
patients experienced more than one SE). Among these the most
common SEs resulting in drug discontinuation were nausea (25%),
headaches (20.8%), mood swings (16.7%) and dizziness (16.7%).
Psychosis as a serious limiting SE was identiﬁed in three patients,
aged 51, 63 and 69 years old respectively, one of whom also
exhibited suicidal ideation. These three patients underwent formal
psychiatric assessment. None of these three patients had any pre-
vious relevant medical history or suffered from any other co-
morbidity. All three were on an anti-cataplectic agent, combined
with dexamphetamine in two of them and with modaﬁnil in one
another. Of note, psychotic symptoms resolved after discontinua-
tion of sodium oxybate in all three patients.
No signiﬁcant correlation between total SE incidence and age,
BMI, gender and ﬁnal dose of sodium oxybate prescribed was
identiﬁed, but analysis of individual SEs demonstrated age to be
associated with risk of psychosis (r¼ 0.234, p¼ 0.027) and enuresis
(r ¼ 0.251, p ¼ 0.017), and BMI with dizziness and bad taste
(r ¼ 0.279, p ¼ 0.021 and r ¼ 0.257, p ¼ 0.034 respectively). No
statistically signiﬁcant predictionmodel was generated using as the
dependent variable any SE incidence and as independent variables
age, BMI, gender, optimum dose of sodium oxybate prescribed,
number of other concomitant drugs, reduction of other drug dos-
ages, baseline ESS, and DESS (p ¼ 0.333).
For those SEs resulting in discontinuation, time to drug discon-
tinuation was added as an independent variable. Correlation anal-
ysis revealed that SEs resulting in drug discontinuation tended to
occur early after the initiation of sodium oxybate, and thus at lower
doses of the drug (r ¼ 0.240, p ¼ 0.027 and r ¼ 0.482, p < 0.001
respectively). The time to drug discontinuation due to limiting SEs
had a median 12 months (interquartile range 3.7e22.0). With
regards to speciﬁc SEs that led to drug discontinuation, several
correlations were found, amongst which age was again associated
with psychosis (r ¼ 0.238, p ¼ 0.028) and enuresis (r ¼ 0.252,
p ¼ 0.020) but also with headaches (r ¼ 0.251, p ¼ 0.017) and BMI
with dizziness (r ¼ 0.291, p ¼ 0.021) and bad taste (r ¼ 0.266,
p ¼ 0.035). When binary forward stepwise model analysis was
performed aiming to predict the occurrence of any limiting SE using
as independent variables the factors from the previous binary
regression analysis (age, BMI, gender, optimum dose of sodium
Table 2
Observed side effects in 90 patients with narcolepsy with cataplexy
treated with sodium oxybate.
n (%)
General
Amenorrhea 1 (1.1%)
Appetite loss 6 (6.6%)
Asthenia 1 (1.1%)
Bad taste 6 (6.6%)
Facial swelling 1 (1.1%)
Pain 4 (4.4%)
Peripheral edema 1 (1.1%)
Sweating 3 (3.3%)
Urinary incontinence 2 (2.2%)
Psychiatric
Anxiety 4 (4.4%)
Hallucinations 2 (2.2%)
Mood swings 14 (15.5%)
Psychosis 3 (3.3%)
Suicidal ideation 1 (1.1%)
Cardiac
Hypertension 1 (1.1%)
Palpitations 1 (1.1%)
Infections
Viral infection 1 (1.1%)
Gastrointestinal
Diarrhea 1 (1.1%)
Dry mouth 1 (1.1%)
Faecal incontinence 1 (1.1%)
GERD 2 (2.2%)
Nausea 16 (17.7%)
Vomit 6 (6.6%)
Neurological
Cramps 1 (1.1%)
Dizziness 9 (9.9%)
Headaches 7 (7.7%)
Impaired concentration 6 (6.6%)
Myoclonus 1 (1.1%)
Unresponsiveness 4 (4.4%)
Sleep disorders
Enuresis 11 (12.2%)
Insomnia 2 (2.2%)
Sleep walking 7 (7.7%)
Worse cataplexy 1 (1.1%)
Worse OSA 3 (3.3%)
GERD: gastroesophageal reﬂex disease, OSA: obstructive sleep apnea.
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oxybate prescribed, number of other concomitant drugs, reduction
of other drug dosages, baseline ESS and DESS) plus the time to drug
discontinuation, increasing age (OR ¼ 1.060, 95% CI ¼ 1.004e1.119,
p ¼ 0.036) and shorter time to drug discontinuation (OR ¼ 0.924,
95% CI ¼ 0.886e0.963, p < 0.001) were both found to be associated
with an increased likelihood of a limiting SE to occur.
7. Discussion
Few studies have explored the efﬁcacy and safety of sodium
oxybate outside the strictly regulated environment of a prospective
controlled trial. Our cohort had 3116 patient-months of drug
exposure, to our knowledge the highest exposure time described in
the literature to date. These results support previous ﬁndings
regarding the efﬁcacy and safety of the drug [10,12,13,17e21]. It
should be noted however that, owing to limitations of access to
sodium oxybate in the United Kingdom, our cohort is likely to
reﬂect a more severe or refractory phenotype than the cohorts in
previous trials, with patients who have more severe EDS and more
severe cataplexy, and who are refractory to traditional stimulants
and anti-cataplectic agents.
The data presented highlight a number of salient points relevant
to clinical practice. In this retrospective “real-life” analysis, sodium
oxybate proved to be efﬁcacious in terms of reduction observed
in daytime sleepiness. Despite our patients having a higher
baseline ESS, despite stimulant therapy, than in previous studies
[10,12,13,19,22], the relative reduction in ESS observed in our study
is comparable to those reported in the literature [10,12,13,19,21].
Furthermore, our data suggest that those patients who are sleepier
or who have more severe cataplexy at baseline are the patients that
would be expected to experience the most beneﬁt. The impact of
sodium oxybate on frequency of cataplexy events in our study was
signiﬁcant, but as expected, of a lower magnitude compared to
other studies, since our cohort had already demonstrated itself to
be refractory to traditional anti-cataplectic agents [10,13,22].Whilst
only 10% of patients achieved removal of other drugs for narcolepsy,
approximately half of the patients that remained on sodium oxy-
bate saw a lowering in their other drug dosages. The optimal
maintenance dose could not be predicted by gender, BMI or other
clinical factors.
In our cohort, a higher percentage of SEs leading to drug
discontinuation was observed than in previous studies, perhaps
reﬂecting the impact of co-administration of stimulants and anti-
cataplectic agents, or the longer follow-up period. Over half of
the patients (55.6%) experienced at least one SE, consistent with
previous studies [17,19,21], but 26.6% were forced to stop the drug
due to intolerable SEs. This is signiﬁcantly higher than described in
the literature (4.4%e9.4%) [10,13,17]. Again, this may be because our
cohort consisted of patients with treatment refractory narcolepsy,
with the majority already on other stimulants or/and anti-
cataplectic agents. Additionally, a higher percentage of our pa-
tients received a higher optimized dose of 9 g/night (33%) than in
other studies [10,13,17].
Nausea, mood swings and enuresis were the most frequent SEs,
similar to, and at a comparable rate to, those reported in previous
studies [10,13,17,19,21]. SEs did not appear to be dose-dependent or
gender-related, but seemed more likely to occur in older patients,
andweremore likely to arise early in the treatment course and thus
at lower doses. Our results also provide some indirect support to
concerns that sodium oxybate may worsen sleep-disordered
breathing, with three of our patients on CPAP requiring an in-
crease in CPAP dose [23,24]. This stresses the need to remain vigi-
lant for the development or exacerbation of OSA after the initiation
of sodium oxybate, particularly as it is more common in patients
with narcolepsy [25].
8. Limitations
Patients and data in this cohort were retrospectively identiﬁed
and collected from our clinical records, providing a realistic snap-
shot of the efﬁcacy and safety of sodium oxybate in clinical practice.
While drawing this sample from a single institution signiﬁes
the utilisation of a consistent approach in data collection, a pre-
established side effects list would have offered a more stand-
ardised assessment. As with all retrospective studies, data captured
from the medical records are less reliable than prospective data
entry. Prospective multi-centre studies would therefore add
credence to our ﬁndings.
9. Conclusion
Sodium oxybate is an efﬁcacious and generally safe treatment
of patients with narcolepsy and cataplexy in standard clinical
practice. Signiﬁcant SEs that lead to drug withdrawal are more
common in older patients and tend to occur early after initiation of
the drug.
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